Skip to main content

Table 3 Demographic and clinical characteristics of chronic pancreatitis (CP) patients in the study

From: Rectally administered indomethacin to prevent post-ESWL-pancreatitis (RIPEP): study protocol for a randomized controlled trial

Age

 

 At onset of chronic pancreatitis

 

 At diagnosis of chronic pancreatitis

 

 At presentation with pancreatic stone

 

 At first P-ESWL session

 

Sex

 

 Smoking status

 

Etiology

 

 Alcoholic CP

 

 Idiopathic CP

 

 Hereditary (familial) CP

 

 Metabolic

 

 Traumatic

 

 Others

 

Pain pattern

 

 Painless

 

 Recurrent acute pancreatitis

 

 Recurrent abdominal pain (RP) without significant increase in serum amylase

 

 Recurrent acute pancreatitis or abdominal pain (RAP/P) without significant increase in serum amylase

 

 Chronic pancreatic pain (CPP)

 

Complications

 

 Diabetes

 

 Steatorrhea

 

 Pseudocyst

 

 Ductus choledochus obstruction or stricture

 

 Duodenal stenosis

 

 Pancreatic fistula

 

 Portal hypertension

 

Treatment history

 

 Previous ESWL

 

 Precious ERCP

 

  Successful drainage with previous ERCP

 

  Previous EPT

 

  Previous pancreatic duct stent implantation

 

 Pancreatic surgery history

 

M-ANNHEIM clinical stages

 

 I a/b/c

 

 II a/b/c

 

 III a/b

 

 IV a/b

 
  1. EPT ERCP endoscopic retrograde cholangiopancreatography, ESWL extracorporeal shock wave lithotripsy